David Lye

Citée par

	Toutes	Depuis 2020
Citations	50417	44984
indice h	88	72
indice i10	296	250

14000

7000

3500

10500

2010201120122013201420152016201720182019202020212022202320242025152 202 249 271 414 520 568 703 814 1134 6639 13033 11138 7497 5448 688

Accès public

Tout afficher

201 articles

7 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Yee-Sin LeoProfessor of National Centre for Infectious DiseasesAdresse e-mail validée de ncid.sg
Barnaby YoungNational Centre for Infectious DiseasesAdresse e-mail validée de ncid.sg
Vernon LeeSaw Swee Hock School of Public Health; Ministry of Health, SingaporeAdresse e-mail validée de moh.gov.sg
Angela ChowTan Tock Seng Hospital Singapore; Lee Kong Chian School of MedicineAdresse e-mail validée de ttsh.com.sg
Laurent ReniaProfessor of Infectious Diseases, Lee Kong Chian School of Medicine, Nanyang TechnologicalAdresse e-mail validée de ntu.edu.sg
Shirin KalimuddinConsultant, Department of Infectious Diseases, Singapore General HospitalAdresse e-mail validée de singhealth.com.sg
Tun-Linn TheinNational Centre for Infectious Diseases; Tan Tock Seng Hospital; Chulalongkorn UniversityAdresse e-mail validée de ncid.sg
Linfa WangEID Programme, Duke-NUS Medical SchoolAdresse e-mail validée de duke-nus.edu.sg
Calvin J Chiew, MBBS MPH FAMSNational Centre for Infectious Diseases, SingaporeAdresse e-mail validée de mail.harvard.edu
Paul A TambyahNational University of SingaporeAdresse e-mail validée de nus.edu.sg
Sean W. X. OngUniversity of Toronto; University of Melbourne; National Centre for Infectious DiseasesAdresse e-mail validée de mail.utoronto.ca
Chen I-Cheng MarkNational Centre for Infectious DiseasesAdresse e-mail validée de ncid.sg
Low JGDrAdresse e-mail validée de singhealth.com.sg
Chee Wah TanInfectious Diseases Translational Research Programme, NUSAdresse e-mail validée de duke-nus.edu.sg
Po Ying ChiaNational Centre for Infectious DiseasesAdresse e-mail validée de ttsh.com.sg
Dale FisherMedicine, National University of SingaporeAdresse e-mail validée de nus.edu.sg
Tat Ming NGTan Tock Seng Hospital, SingaporeAdresse e-mail validée de ttsh.com.sg
Siew-Wai FongResearch Scientist, ASTAR IDLabsAdresse e-mail validée de idlabs.a-star.edu.sg
Sophia ArchuletaNational University of SingaporeAdresse e-mail validée de nus.edu.sg
Benjamin OngProfessor, Department of Medicine, National University of SingaporeAdresse e-mail validée de nus.edu.sg

Suivre

David Lye

National Centre for Infectious Diseases; Tan Tock Seng Hospital; Lee Kong Chian School of Medicine

Adresse e-mail validée de ttsh.com.sg

COVID-19 dengue antimicrobial resistance antimicrobial stewardship


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020	6504	2020
Autoantibodies against type I IFNs in patients with life-threatening COVID-19 P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ... Science 370 (6515), eabd4585, 2020	2754	2020
Remdesivir for the treatment of Covid-19—preliminary report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1836, 2020	2717	2020
Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore BE Young, SWX Ong, S Kalimuddin, JG Low, SY Tan, J Loh, OT Ng, ... Jama 323 (15), 1488-1494, 2020	2625	2020
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen, M Ogishi, ... Science 370 (6515), eabd4570, 2020	2369	2020
Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021	1940	2021
Remdesivir for 5 or 10 days in patients with severe Covid-19 JD Goldman, DCB Lye, DS Hui, KM Marks, R Bruno, R Montejano, ... New England Journal of Medicine 383 (19), 1827-1837, 2020	1712	2020
Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial CD Spinner, RL Gottlieb, GJ Criner, JRA López, AM Cattelan, ... Jama 324 (11), 1048-1057, 2020	1556	2020
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction CW Tan, WN Chia, X Qin, P Liu, MIC Chen, C Tiu, Z Hu, VCW Chen, ... Nature biotechnology 38 (9), 1073-1078, 2020	1280	2020
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail J Hansen, A Baum, KE Pascal, V Russo, S Giordano, E Wloga, BO Fulton, ... Science 369 (6506), 1010-1014, 2020	1050	2020
Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients PY Chia, KK Coleman, YK Tan, SWX Ong, M Gum, SK Lau, XF Lim, ... Nature communications 11 (1), 2800, 2020	990	2020
Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures R Pung, CJ Chiew, BE Young, S Chin, MIC Chen, HE Clapham, AR Cook, ... The Lancet 395 (10229), 1039-1046, 2020	822	2020
Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients AT Tan, M Linster, CW Tan, N Le Bert, WN Chia, K Kunasegaran, ... Cell reports 34 (6), 2021	735	2021
Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a … PNA Harris, PA Tambyah, DC Lye, Y Mo, TH Lee, M Yilmaz, TH Alenazi, ... Jama 320 (10), 984-994, 2018	702	2018
Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey A Versporten, P Zarb, I Caniaux, MF Gros, N Drapier, M Miller, V Jarlier, ... The Lancet Global Health 6 (6), e619-e629, 2018	667	2018
Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients IYJ Seah, DE Anderson, AEZ Kang, L Wang, P Rao, BE Young, DC Lye, ... Ophthalmology 127 (7), 977-979, 2020	546	2020
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021	541	2021
Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study BE Young, SW Fong, YH Chan, TM Mak, LW Ang, DE Anderson, CYP Lee, ... The lancet 396 (10251), 603-611, 2020	488	2020
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study PY Chia, SWX Ong, CJ Chiew, LW Ang, JM Chavatte, TM Mak, L Cui, ... Clinical microbiology and infection 28 (4), 612. e1-612. e7, 2022	422	2022
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients CM Poh, G Carissimo, B Wang, SN Amrun, CYP Lee, RSL Chee, ... Nature communications 11 (1), 2806, 2020	406	2020

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs